tbuckley/cabot-search huggingface dataset:
COPD: Is there association between physical activity and depression/anxiety?
Authors: Helena Azcuna, Cristobal Esteban, Inmaculada Arostegi, Javier Moraza, Myriam Aburto, Amaia Aramburu, Mikel Egurrola
Journal: European Respiratory Journal (2014)

INTRODUCTION: COPD is a complex disease that is associated to sistemic effects, in addition to chronic airflow obstruction. These symptoms restrict the daily life and physical activity of the patients with a high prevalence of anxiety and depression that is often underdiagnosed.

OBJECTIVE: The aim of the study is to asses if there is any association between physical activity and anxiety/depression levels in COPD patients.

MATERIALS AND METHODS:543 patients were selected from our pneumology area from January 2003 to January 2004. They were diagnosed of COPD in the 6 months prior and stayed stable at least 6 weeks. An initial evaluation was made, where we included, among other aspects of disease, depression and anxiety by Hospital Anxiety and Depression (HAD) questionnaire and physical activity (PA) (walked distance 3 days per week) and we set up 3 categories: low the patients who walked less than 3 km per day, medium 3-6km and high more than 6 km. Depression and anxiety level and physical activity changes were analyzed during 5 years.

RESULTS: 324 (60%) patients fulfill 5 years of follow up. We analyze the overall relationship between AP changes and mean level of depression with a statistical significative diference (p=0.025). Data gave evidence of statistical significance in patients who manteined low AP during the follow up with change of -1,20 of depression level (CI -1,84-0,56) and in patients who decreced AP from high to medium/low with change of -0,93 (CI -1,67-0,18) in depression level and incresed 1,12 (CI 95% 0,27-1,97) anxiety level.

CONCLUSION: An association was found between the change of physical activity level and change of depression level in a COPD patient cohort during 5 years.
Deafness in intrathecal chemotherapy.
Authors: G B Zulian, M S Aapro, A Michel, M Estade, C Baud, R Häusler
Journal: Journal of Clinical Oncology (1985)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1985.3.11.1562 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3840525 Deafness in intrathecal chemotherapy. G B ZulianxG B ZulianSearch for articles by this author , M S AaproxM S AaproSearch for articles by this author , A MichelxA MichelSearch for articles by this author , M EstadexM EstadeSearch for articles by this author , C BaudxC BaudSearch for articles by this author , R HäuslerxR HäuslerSearch for articles by this author https://doi.org/10.1200/JCO.1985.3.11.1562 PDF "Deafness in intrathecal chemotherapy.." Journal of Clinical Oncology, 3(11), pp. 1562–1563© 1985 by American Society of Clinical Oncology
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Authors: Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, Jonathan L Halperin, Günter Breithardt, Daniel E Singer, Kenneth W Mahaffey, Graeme J Hankey, Scott D Berkowitz, Christopher C Nessel, Keith A A Fox, Robert M Califf, Jonathan P Piccini, Manesh R Patel
Journal: The Lancet (2015)
Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial
Authors: T. M. Feinstein, L. E. Raez, K. K. Rajasenan, M. K. Gibson, P. Savvides, M. V. Karamouzis, N. Garg, R. Johnson, B. F. Branstetter, A. E. Argiris
Journal: Journal of Clinical Oncology (2008)

6069 Background: P, a multi-targeted antifolate, is well tolerated and has single-agent activity in HNSCC. B is a humanized monoclonal antibody against the vascular endothelial growth factor. In other cancers, various chemotherapies combined with B have produced survival benefits. We are conducting a phase II trial of P and B in recurrent or metastatic (R/M) HNSCC (ASCO 2006;A6049). Methods: Eligible pts have R/M HNSCC with no prior systemic therapy (chemotherapy as part of initial potentially curative therapy without P or B is allowed, if completed >6 months earlier), ECOG performance status 0–1, and measurable disease. Pts with history of gross hemoptysis, unequivocal invasion of major vessels by tumor or receiving therapeutic anticoagulation are excluded. Treatment consists of P 500 mg/m2 and B 15 mg/kg, given intravenously every 21 days, until disease progression or intolerable toxicity. All pts receive folic acid, vitamin B12, and corticosteroid prophylaxis. The primary endpoint is the time to progression (TTP) with a sample size of 40 pts (one stage design). Results: 25 pts have been enrolled. Median age 62 years (36–85); male/female 22/3; PS 0/1: 9/16; prior chemotherapy: 19; primary site: oropharynx (14), oral cavity (4), unknown primary (3), larynx (3), hypopharynx (1). A median 6 cycles of therapy were delivered (1- 11). With a median follow up of 8 months, the median TTP was 7 months (95% CI, 3.7–10.3). Best response in 22 evaluable pts: CR: 3, PR: 5, SD: 13, PD: 1, with overall response rate of 36%. There were two grade (G) 5 toxicities; 1 pt died after 8 cycles from sepsis presumably related to aspiration, with G 3 neutropenia; 1 pt died after 5 cycles from tracheal bleeding (a previously re-irradiated area) triggered by suctioning. 3 additional pts had G 3 hemorrhage (2 tumor-related and 1 due to gastric ulcer post gastrostomy tube placement). Other G 3 toxicities were dysphagia (3), fatigue (2), infection (2), hypokalemia (2), hyponatremia (2), neutropenia (2), anorexia (1), mucositis (1). There were no G 4 toxicities. Conclusions: Updated results show that P plus B is associated with bleeding complications but very encouraging efficacy in R/M HNSCC. Study accrual continues. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology, Lilly Oncology
Prediction of aggressive prostate cancer on biopsy using classification and regression tree analysis (CART)
Authors: S. Spurgeon, A. Riavadeneira, L. M. Peters, H. Yi-Ching, T. M. Beer, M. Mori, M. Garzotto
Journal: Journal of Clinical Oncology (2004)

4720 Background: Prostate cancer screening allows for the early detection of disease; however, not all cancer patients are candidates for intervention due patient co-morbidities and the indolent nature of some tumors. Distinguishing patients who are likely to harbor aggressive prostate cancer could significantly reduce the number of prostate biopsies performed in men that would be offered treatment only in the presence of high-grade prostate cancer. Methods: Data were collected on 1,563 consecutive referred men with a serum prostate specific antigen (PSA) of ≤ 10 ng/ml who underwent an initial prostate biopsy. Predictors of aggressive cancer (defined as Gleason sum ≥ 7) were identified using CART analysis that considered demographic variables (age, race, reason for referral, history of vasectomy, and family history), digital rectal exam findings, serum prostate–specific antigen levels (PSA), TRUS findings (prostate volume, hypoechoic lesion) and PSA density (serum PSA/prostate volume). The model building was carried out on 70% of the data (randomly selected training set) and study validation was carried using the remaining 30% of the data (validation set). Results: 408 (26.1%) of men had prostate cancer. Of these, 129 (31.6%) were determined to be Gleason ≥ 7. CART analysis created a decision tree that identified the following groups to be at high-risk for the detection of Gleason ≥ 7 prostate cancer: (1) PSAD > 0.165 ng/ml/cc; and (2) PSAD ≤ 0.165 ng/ml/cc and age > 57.5 years, and prostate volume > 22.7 cc. The performance of the decision tree is shown below: Conclusions: CART analysis successfully identified groups at high risk for the diagnosis of Gleason ≥ 7 prostate cancer. Application of this model to clinical practice would result in a 33.5% reduction in unnecessary biopsies when a diagnosis of high-grade prostate cancer would be the primary determinant of subsequent treatment decisions. No significant financial relationships to disclose.
Interest of the simple calculated osteoporosis risk estimation (SCORE) tool for a more rational use of bone densitometry
Authors: Wafa Ben Sedrine, Jean-Pierre Devogelaer, Jean-Marc Kaufman, S. Goemaere, G. Depresseux, Olivier Bruyère, Jean-Yves Reginster
Journal: Annals of the Rheumatic Diseases (2000)
The role of extensive lymphadenectomy in stage I ovarian cancer
Authors: E. G. Munro, N. Karnik Lee, M. K. Cheung, K. Osann, A. Husain, N. N. Teng, D. S. Kapp, J. S. Berek, J. K. Chan
Journal: Journal of Clinical Oncology (2006)

5069 Background: To determine if extent of lymphadenectomy affects the survival of women with stage I ovarian cancer. Methods: Demographic and clinico-pathologic information were obtained from the Surveillance, Epidemiology and End Results Program from 1988–2001 and analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Results: Of the 6,686 women diagnosed with stage I ovarian cancer, 4,092 (61.2%) had stage IA, 392 (5.9%) had stage IB, 1,840 (27.5%) had stage IC, and 362 (5.4%) had unspecified stage I disease. The median age was 53 (range: 1–99). 5,625 (84.1%) were White, 388 (5.8%) Black, 488 (7.3%) Asian, and 185 (2.8%) were Other. All patients underwent primary surgery; of which, 3,824 women had no nodes, 1,533 had &lt;10 nodes, and 1,329 had ≥10 nodes resected. Of the patients who underwent a lymphadenectomy, the median number of nodes resected was 9 (range: 1–84). The extent of lymphadenectomy (0, &lt;10, and ≥10 nodes) increased the survival of patients with stage IC disease from 72.8%, 86.7%, to 90.1% (p &lt; 0.0001), but not in those with stage IA (p = 0.07) or stage IB (p = 0.04) disease. In patients with non-clear cell epithelial carcinoma, the extent of lymphadenectomy was associated with improved 5-year disease-specific survivals of 85.6%, 93.3%, and 93.5%, respectively (p &lt; 0.0001). However, the benefit associated with an extensive lymphadenectomy was not evident in clear cell (p = 0.09), sarcoma (p = 0.33), germ cell (p = 0.55), or sex cord stromal tumors of the ovary (p = 0.99). Similarly, patients with grade 3 disease had an improved survival associated with the extent of lymph node resection, 74.4%, 87.5%, to 90.5% (p &lt; 0.0001), but not in those with grade 1 (p = 0.18) or grade 2 (p = 0.27) disease. In multivariate analysis, a more extensive lymphadenectomy remained significant as an independent prognostic factor for improved survival after adjusting for all other independent prognostic factors including age, surgery, histology, stage, and grade. Conclusions: Our findings suggest that the extent of lymphadenectomy was associated with an improvement in the survival of women with stage IC ovarian cancer. No significant financial relationships to disclose.
Is There a Relationship Between Patient'S Satisfaction of the Diagnosis Announcement Device and Chemotherapy-Induced Nausea and Vomiting?
Authors: S. Gouerant, A.E. Dugue, J. Vanboeckstael, D. Allouache, S. Noal, A. Faveyrial, C. Delcambre, M. Galais, A. Lefebvre, E. Sevin, F. Polycarpe, I. Hrab, P.E. Brachet, L. Kaluzinski, M.D. Ngo, B. Vie, N. Lemenand, J. Grellard, B. Clarisse, F. Joly Lobbedez
Journal: Annals of Oncology (2014)
Factors associated with high smoking cessation motivation
Authors: Zahra Hessami, Hooman Sharifi, Mohammadreza Masjedi
Journal: European Respiratory Journal (2014)

Background  Smoking is one of the major causes of cancer, heart and pulmonary diseases. One of the essential steps in the tobacco control programs is persuading the smokers to quit smoking. Being motivated is an essential step in smoking cessation process. In this study we investigated factors that related with level of smoking cessation motivation among participants of smoking cessation clinic.   Material and Method:   This cross-sectional study was conducted on the volunteers of smoking cessation clinic in Tehran. Their demographic information and cigarette status were assessed through a questionnaire. They underwent tests for motivation degree assessment by Q-mat test. Factors associated with degree of motivation to quit was evaluated by using Spss software.   Results:   Overall, 345 individuals were studied. The mean (SD) age of the subjects was 37.6±11.04 (range: 18-73 years). 311(90.1%) participants were male with a mean (SD) age of 37.5±11.2 years. The mean of Q-mat test was 15.5±5.The mean of Q-MAT test significantly associated with higher nicotine dependency, older age and being male.  Conclusion:  Our finding revealed that high nicotine dependency is associated with low willingness to quit. Motivational degree among men and older age (more than 60 years old) is significantly higher. It is suggested that this study conduct in larger sample size among smokers population.
Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results.
Authors: J P Jacobs, K J Murray, C J Schultz, J F Wilson, M S Goswitz, C W Stevens, J D Cox
Journal: Journal of Clinical Oncology (1993)

PURPOSE To report the long-term results of central lymphatic irradiation for stage III nodular malignant lymphoma. PATIENTS AND METHODS Between 1969 and 1985, 34 patients (26 with nodular poorly differentiated lymphoma, four with nodular mixed lymphocytic/histiocytic lymphoma, and four with nodular histiocytic lymphoma) were treated with central lymphatic irradiation. Median age of the group was 51 years (range, 30 to 73). There were 15 men and 19 women. Staging work-up included a physical examination and bone marrow biopsy in all patients. Seventy-four percent had a lymphangiogram (LAG) and 44% a laparotomy (LAP). Eighty-two percent had either a LAP or a LAG. Thirty-two patients were Ann Arbor stage IIIA and two were stage IIIB. All patients received lymphatic irradiation that encompassed cervical, supraclavicular, axillary, mediastinal, paraaortic, mesenteric, pelvic, and femoral lymphatics to total doses ranging from 20 to 30 Gy in 1.0- to 1.8-Gy fractions. Waldeyer's ring was initially treated in 17 patients. Follow-up information is available on all 34 patients. Median follow-up is 9 years, 8 months (range, 15 to 244 months). RESULTS Life-table actuarial overall, disease-free, and cause-specific survival rates at 15 years are 28%, 40%, and 46%, respectively. Only one relapse was observed after 9 years. Disease-free survival was significantly improved in patients with five or fewer sites of involvement (P = .02). Age, sex, B symptoms, histology, and technique of irradiation were not prognostically significant. Salvage therapy, including further irradiation and/or chemotherapy, was delivered to 20 patients. Ten percent of these patients remain alive without evidence of disease. Toxicity data were available for the patients treated at the Medical College of Wisconsin (MCW). Radiation Therapy Oncology Group (RTOG) acute hematologic, gastrointestinal, and salivary toxicity scores were &lt; or = 2 in 83% of patients. Late toxicity scores were &lt; or = 2 in 96%. Persistent xerostomia was noted in 23% of patients who received initial treatment to Waldeyer's ring. CONCLUSION These results suggest that initial comprehensive central lymphatic irradiation may be the preferred approach to achieve a durable relapse-free interval for this group of patients.
Clinical and biological implication of defective p53 pathway in multiple myeloma (MM)
Authors: W. J. Chng, T. Price-Troska, S. Van Wier, S. Jacobus, E. Blood, K. Henderson, M. M. Oken, B. Van Ness, P. Greipp, R. Fonseca
Journal: Journal of Clinical Oncology (2006)

17516 Background: The p53 tumor suppressor is commonly inactivated by mutations. Even in tumors without mutations, there are defects in the response to p53 activation. In MM, the prognostic significance of p53 mutation is unknown, while there has been no systematic study of p53 function. We seek to address these issues in this study. Methods: p53 mutation was studied by conformation sensitive gel electrophoresis with primers encompassing exons 1 to 10 followed by sequencing of DNA fragments with altered electrophoretic pattern in newly diagnosed MM patients entered into ECOG E9486 trial where patients were randomized to receive variations of melphalan-based conventional chemotherapy (VBMCP). Fisher’s exact tests were used to compare variables between patients. Kaplan-Meier survival curves were compared using the log-rank test. To investigate p53 function, we analyzed the expression of p53, and 3 of its transcriptional targets, APAF1, p21 and MDM2, in a separate cohort of 15 normal plasma cells (PC), 14 MGUS, 13 smoldering myeloma (SMM) and 101 MM (73 new and 28 relapsed) from the Mayo Clinic who had gene expression profiling performed on the Affymetrix U133A chip (Santa Clara, Ca). Results: Two hundred and sixty-eight patients had enough materials for study and were included in the analysis. The prevalence of p53 mutation was 3% (n = 9). Five of the 9 patients (56%, p = 0.001) with mutations also had p53 deletion (studied by fluorescent in-situ hybridization) resulting in bi-allelic loss of p53. Soft tissue plasmacytomas (37% v 7%, p = 0.018), and among the common translocations, t(4;14) and t(14;16) (50% v 18%) were more common in patients with p53 mutations. Despite similar response to treatment, those with p53 mutation had very short OS (16.7 v 41.4 months, p &lt; 0.001). There was induction of p53 expression in MGUS and SMM with concurrent induction of APAF1, p21 and MDM2 whereas loss of this pattern was frequent in MM (45% in new MM and 60% in relapse MM compared to 15% in MGUS/SMM (p = 0.03)). Conclusions: p53 mutations are relatively rare in newly diagnosed MM patients but portend a short survival. However, functional abnormalities of p53 are prevalent and may be important in progression from MGUS/SMM to MM. [Table: see text]
Clinical experience with oral vinorelbine (NVB) plus prednisone as first- or second-line chemotherapy of metastatic hormone- refractory prostate cancer (HRPC)
Authors: J. M. Cervera, I. Garcia-Carbonero, R. Girones, M. Beltran, V. Calderero, M. L. Gonzalvez, M. Domenech, N. Diaz, P. Jimenez-Lacave, A. Gonzalez
Journal: Journal of Clinical Oncology (2009)

e16151 Background: IV NVB plus hydrocortisone (HC) compared with HC alone resulted in improved clinical benefit, progression-free survival (PFS) and PSA response rate in HRPC. The oral formulation of NVB avoids the side effects associated with the IV injection, may reduce administration and toxicity-related costs and is easy to administer. Due to these advantages, single agent oral NVB treatment could be considered as an optimal option for patients (p) with HRPC previously treated with a taxane or as first-line treatment when a taxane is not indicated. We retrospectively evaluated efficacy and toxicity or oral NVB administered as single agent as first or second-line chemotherapy of metastatic HRPC. Methods: Retrospectively data was collected from p with metastatic HRPC treated with oral NVB 80 mg/m 2 days 1 and 8, with a prior test of myelosensitivity at 60 mg/m 2 for the first cycle, plus prednisone 10 mg/day. Patients had received a taxane as first-line treatment or had a documented contraindication to receiving docetaxel. 1 cycle was equivalent to a 3-week period. Results: Data on 55 p treated in 11 Spanish centres were included for assessment. Median age was 72.5 years (range 54–86). ECOG PS 0, 17%; 1, 66%; 2, 17%. Median PSA 75 ng/mL. Prior taxane chemotherapy, 87%. Median number of cycles was 4 (range 1–6). 53.8% of p could escalate oral NVB to 80 mg/m 2 . 221 cycles were performed, 4.1% were delayed and 3.2% had a dose reduction. Grade 3–4 events were infrequent and mainly haematological: neutropenia (5.5% of p), anemia (3.6%), pain (3.6%), infection (1.8%), asthenia (1.8%), respiratory (1.8%). No febrile neutropenia was reported. 49 p were evaluable for PSA response rate; complete plus partial response was observed in 20.4% (95% CI: 10.2% - 34.3%) and PSA stable was reported in 40.8%. 29 p were evaluable for measurable disease; among them, 20.7% presented partial response and 44.8% stable disease. Median follow-up was 4.3 months. Survival status: 49 p (89.1%) are alive and 6 p (10.9%) died. Conclusions: Oral NVB is a safe and active regimen in previous chemotherapy treated HRPC. For those p who can not receive a taxane as first-line therapy, oral NVB can also be considered as an effective first-line treatment. No significant financial relationships to disclose.
The effect of anti-IGF1 therapy on muscle mass in metastatic pancreatic cancer.
Authors: David R. Fogelman, Mohamed Aly Khalil, Manal Hassan, Naveen Garg, Milind M. Javle, Matthew H. G. Katz, Holly Michelle Holmes, James L. Abbruzzese
Journal: Journal of Clinical Oncology (2013)

4064 Background: IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown. Methods: We evaluated muscle mass at L3 in patients enrolled in a randomized phase II study of MK-0646 (M), a monoclonal antibody directed against the IGF-1 protein, in patients with metastatic pancreatic cancer (MPC). We used the Slice-o-matic (ver 4.3) software to segregate CT images into muscle and fat components and measured muscle area (cm2) at baseline and after 2 and 4 months of treatment. Patients received either gemcitabine with erlotinib (G+E), G+E+M, or G+M. Differences between the groups were compared using t-tests. Results: 58 patients had both baseline and 2 month imaging available for analysis. Of these, 44 received M and 14 had G+E only. Baseline muscle mass between the two groups was similar: 146 cm2 and 142 cm2, respectively (P=0.47). After two months of treatment, both groups demonstrated decrease in muscle mass: 134 cm2 (8% loss) vs. 130 cm2 (6% loss) (P= 0.19). Of the 37 patients who had either PR or SD at 2 months, there was a non-significant increase in muscle mass loss among the patients receiving M (7.8% vs. 4.5%, p=.31). At 4 months, those remaining patients in the M group lost 6% (n=14) of muscle mass compared to 3% in the non-M group (n=5) (P=0.54). Each 1% loss of muscle mass increased the odds of dropout by 13% (p=.03, CI 1.0-27%) and predicted for poor survival (p=HR 1.08, p=.02). Conclusions: MPC patients can be expected to lose muscle mass even while having clinical benefit (PR or SD) from chemotherapy. Muscle loss correlated with a risk of study drop-out and death. There was a non-significant trend towards greater muscle mass loss in patients on anti-IGF-1R therapy. However, it is unclear if this loss translates into functional differences between patients. Clinical trial information: NCT00769483.
HIV-associated non-Hodgkin's lymphomas: Clinical characteristics and outcome. The experience of the French Registry of HIV-associated Tumors*
Authors: S. Roithmann, M. Toledano, J.M. Tourani, M. Raphael, M. Gentilini, J.A. Gastaut, M. Armengaud, P. Morlat, H. Tilly, B. Dupont, B. Taillan, C. Theodore, D. Donadio, J.-M. Andrieu
Journal: Annals of Oncology (1991)